A new report is expected to make positive progress in the treatment of serious cases of code 19 caused by the new novel coronavirus.
Experts have long been urging people to try the decades-old method of treating sick people more than the blood of those who have recovered from the disease.
Now a new study has found preliminary results of this method which are very encouraging.
A study published in the medical journal The American Medical Association on Friday described the use of the method in dying patients in a Chinese hospital.
These Code 19 patients were tested for experimental blood plasma transfusion and their condition improved significantly.
Although this research was limited and very small in scale and difficult to determine definitively, the findings further reinforce the idea of the usefulness of this method.
The plasma transfusion was announced this week for testing in severe cases in New York, the state most affected by the disease in the United States.
For the study, doctors at Shenzhen Hospital in China used blood plasma on five patients aged 36 to 73 from January 20 to March 25.
These patients were given this plasma 10 to 22 days after hospitalization.
Within 3 days after plasma transfusion, 4 out of 5 patients had their body temperature returned to normal, and 4 out of 5 patients had severe respiratory distress within 12 days.
The results of the study, published on Friday, show that 3 patients were discharged from the hospital while 2 were in stable condition, but were currently feeling the need for a ventilator.
Other medical experts on the study said it was limited, while the patients were also being given experimental antiviral drugs and steroids, making it difficult to say definitively about the efficacy of plasma transfusions.
But Chinese scientists involved in the study said the results highlighted the possibility of using antibodies to healthy people for plasma therapy, which could help more sick people get rid of the virus and improve their condition.
This method was also used during the 2002 SARS pandemic and the 2009 swine flu pandemic.
In this new study, this experimental method was tested by collecting blood donations from people with COD 19 health and receiving plasma from their blood and transferring it to critically ill patients on the same day.
If this method proves effective on a large scale, the biggest challenge will be to get blood donations from healthy people.
Earlier this week, a study by the Washington University School of Medicine in the United States found that the blood of people recovering from Code 19 would be able to treat critically ill patients and prevent others from becoming infected.
This method was used during the Spanish flu pandemic of 1918 before the availability of vaccines or antiviral drugs.
This procedure takes into account the fact that healthy patients have powerful antibodies in their blood that are trained to fight the virus.
There is currently no cure for the new novel coronavirus, and a vaccine is unlikely to be available until the end of this year or the first half of next year.
According to Dr. Jeffrey Henderson, an associate professor at the University of Washington, "the use of serums derived from the blood of recently recovered patients seems a very old idea, but historically it has been a useful method."
"Using it, we were able to prevent and treat viral infections such as measles, polio and influenza, but once the vaccine was ready, the technique was forgotten," he added.
"As long as we develop specific drugs and vaccines related to Code 19, this method will be able to help save lives," he said.
When there was no cure for the Spanish flu pandemic, doctors used the blood serum of recovering patients to help many recovers.
Blood plasma and serum are clear blood fluids and both are equipped with antibodies, but plasma also contains a few other helpful proteins that are not present in serum.
Prior to Washington University, Johns Hopkins University and the Mayo Clinic also began trials on the Code 19 method.
The recommendations were submitted to the US Food and Drug Administration on March 18 and are awaiting permission to test them on humans.
Dr. Jeffrey Anderson said that this is a step that needs to be taken immediately, it is faster than the preparation of medicine because it will only require plasma donation and transplantation.
"As soon as an individual recovers from Code 19 and walks around us, he or she will be a potential donor to us and we will be able to use the blood bank system to obtain plasma and distribute it to patients in need," he said. If implemented, it could provide a lifeline in the early stages of the epidemic.
The research team is now requesting blood donations from healthy patients, from which Halazma will be isolated and transferred to sick people after screening for toxic substances and viruses.